Ruth Jensen Walton
Occupational Therapy in Bountiful, UT
License number
Utah 9434553-4201
Issued Date
Jun 9, 2015
Expiration Date
May 31, 2017
Category
Occupational Therapy
Type
Occupational Therapist
Address
Address
Bountiful, UT
Education
UNIVERSITY OF UTAH, May 7, 2015
Professional information
Metabotropic Glutamate Receptor Antagonists And Their Use For Treating Central Nervous System Diseases
US Patent:
7053104, May 30, 2006
Filed:
Aug 5, 2002
Appl. No.:
10/211523
Inventors:
Bradford C. Van Wagenen - Salt Lake City UT, US
Scott T. Moe - Ann Arbor MI, US
Daryl L. Smith - Fishers IN, US
Susan M. Sheehan - Dexter MI, US
Irina Shcherbakova - Salt Lake City UT, US
Ruth Walton - Bountiful UT, US
Richard Trovato - Salt Lake City UT, US
Robert Barmore - Salt Lake City UT, US
Eric G. Delmar - Salt Lake City UT, US
Thomas M. Stormann - Salt Lake City UT, US
Scott T. Moe - Ann Arbor MI, US
Daryl L. Smith - Fishers IN, US
Susan M. Sheehan - Dexter MI, US
Irina Shcherbakova - Salt Lake City UT, US
Ruth Walton - Bountiful UT, US
Richard Trovato - Salt Lake City UT, US
Robert Barmore - Salt Lake City UT, US
Eric G. Delmar - Salt Lake City UT, US
Thomas M. Stormann - Salt Lake City UT, US
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31/47, C07D 215/14
US Classification:
514311, 546169, 546 90, 514291
Abstract:
The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
Compounds For Alzheimer's Disease
US Patent:
7678823, Mar 16, 2010
Filed:
Apr 4, 2007
Appl. No.:
11/696526
Inventors:
Rachel Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Sandy UT, US
Mark B. Anderson - Salt Lake City UT, US
Kenton Zavitz - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Sandy UT, US
Mark B. Anderson - Salt Lake City UT, US
Kenton Zavitz - Salt Lake City UT, US
Assignee:
Myriad Pharmaceticals, Inc. - Salt Lake City UT
International Classification:
A61K 31/416, C07D 209/04
US Classification:
514412, 548516
Abstract:
The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH, -L-C(═O)NH(Calkyl), -L-C(═O)N(Calkyl), -L-S(═O)(Calkyl), -L-S(═O)NH, -L-S(═O)N(Calkyl), -L-S(═O)NH(Calkyl), -L-C(═O)NHOH, -L-C(═O)CHNH, -L-C(═O)CHOH, -L-C(═O)CHSH, -L-C(═O)NHCN, -L-NHC(═O)OR, -L-C(═O)NHR, -L-NH(C═O)NHR, -L-C(═O)N(R), -L-NH(C═O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
Compounds For Alzheimber's Disease
US Patent:
2010018, Jul 22, 2010
Filed:
Mar 8, 2010
Appl. No.:
12/719672
Inventors:
Rachel Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Salt Lake City UT, US
Mark B. Anderson - Oakland CA, US
Kenton Zavitz - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Salt Lake City UT, US
Mark B. Anderson - Oakland CA, US
Kenton Zavitz - Salt Lake City UT, US
Assignee:
Myriad Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
C07D 413/10, C07D 209/60, C07D 209/08, C07D 403/10, C07D 401/04, C07D 403/04
US Classification:
544143, 548427, 548516, 548254, 5462774, 544297
Abstract:
The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH, -L-C(═0)NH(Calkyl), -L-C(═O)N(Calkyl), -L-S(═O)(Calkyl), -L-S(═O)NH, -L-S(═O)N(Calkyl), -L-S(═O)NH(Calkyl), -L-C(═O)NHOH, -L-C(═O)CHNH, -L-C(═O)CHOH, -L-C(═O)CHSH, -L-C(═O)NHCN, -L-NHC(═O)OR, -L-C(═O)NHR, -L-NH(C═O)NHR, -L-C(═O)N(R), -L-NH(C═O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
Compounds For Alzheimer's Disease
US Patent:
2012022, Sep 6, 2012
Filed:
Apr 13, 2012
Appl. No.:
13/447115
Inventors:
Rachel Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Riverton UT, US
Mark B. Anderson - Orinda UT, US
Kenton Zavitz - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Riverton UT, US
Mark B. Anderson - Orinda UT, US
Kenton Zavitz - Salt Lake City UT, US
Assignee:
Myrexis, Inc. - Salt Lake City UT
International Classification:
A61K 31/5377, A61K 31/4985, A61K 31/437, A61K 31/4439, C07D 413/14, A61K 31/422, A61K 31/403, C07D 403/10, C07D 209/18, C07D 413/10, A61K 31/501, C07D 471/06, C07D 401/04, C07D 417/04, C07D 413/04, C07D 491/10, C07D 209/90, A61K 31/404, C07D 209/12, C07D 413/08, C07D 401/14, C07D 405/14, A61P 25/28, A61K 31/5025
US Classification:
5142352, 514248, 514250, 51425201, 51425505, 514292, 514339, 514365, 514378, 514409, 514411, 514415, 514419, 544143, 544234, 544238, 544405, 546 84, 5462767, 5462774, 548214, 548247, 548254, 548411, 548427, 548509, 548510
Abstract:
The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH, -L-C(═O)NH(Calkyl), -L-C(═O)N(Calkyl), -L-S(═O)(Calkyl), -L-S(═O)NH, -L-S(═O)N(Calkyl), -L-S(═O)NH(Calkyl), -L-C(═O)NHOH, -L-C(═O)CHNH, -L-C(═O)CHOH, -L-C(═O)CHSH, -L-C(═O)NHCN, -L-NHC(═O)OR, -L-C(═O)NHR, -L-NH(C═O)NHR, -L-C(═O)N(R), -L-NH(C═O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
Compounds For Alzheimer's Disease
US Patent:
2013026, Oct 3, 2013
Filed:
Mar 13, 2013
Appl. No.:
13/801348
Inventors:
John Manfredi - , US
Christine Klein - Salt Lake City UT, US
Leena Bhoite - Salt Lake City UT, US
John Manfredi - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Lawrence KS, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Draper UT, US
Mark B. Anderson - Orinda CA, US
Kenton Zavitz - Salt Lake City UT, US
Christine Klein - Salt Lake City UT, US
Leena Bhoite - Salt Lake City UT, US
John Manfredi - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Lawrence KS, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Draper UT, US
Mark B. Anderson - Orinda CA, US
Kenton Zavitz - Salt Lake City UT, US
International Classification:
C07D 403/04, C07D 417/04, C07D 413/10, C07D 401/04, C07D 405/04
US Classification:
5142352, 5462774, 514339, 544331, 514275, 548465, 514414, 548194, 514370, 5482648, 514383
Abstract:
The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).
Pyrrole Derivatives As Therapeutic Compounds
US Patent:
7714022, May 11, 2010
Filed:
Mar 27, 2008
Appl. No.:
12/057140
Inventors:
Warren S. Weiner - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya I. Klimova - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Mark B. Anderson - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya I. Klimova - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Mark B. Anderson - Salt Lake City UT, US
Assignee:
Myriad Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31/40, C07D 207/30
US Classification:
514427, 548563
Abstract:
Novel pyrrole derivatives are disclosed as Aβ-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβpeptide.
Pyrrole Derivatives As Therapeutic Compounds
US Patent:
8217073, Jul 10, 2012
Filed:
May 6, 2010
Appl. No.:
12/775253
Inventors:
Warren S. Weiner - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya I. Klimova - Sandy UT, US
Ruth J. Walton - Bountiful UT, US
Mark B. Anderson - Oakland CA, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya I. Klimova - Sandy UT, US
Ruth J. Walton - Bountiful UT, US
Mark B. Anderson - Oakland CA, US
Assignee:
Myrexis, Inc. - Salt Lake City UT
International Classification:
A61K 31/40, C07D 207/30
US Classification:
514427, 548563
Abstract:
Novel pyrrole derivatives are disclosed as Aβ-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβpeptide.